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Inhibitors against the NS3-4A protease of hepatitis C virus
(HCV) have proven to be useful drugs in the treatment of HCV
infection. Although variants have been identified with muta-
tions that confer resistance to these inhibitors, themutations do
not restore replicative fitness and no secondary mutations that
rescue fitness have been found. To gain insight into themolecu-
lar mechanisms underlying the lack of fitness compensation, we
screened known resistance mutations in infectious HCV cell
culture with different genomic backgrounds. We observed that
the Q41Rmutation of NS3-4A efficiently rescues the replicative
fitness in cell culture for virus variants containing mutations at
NS3-Asp168. To understand how the Q41Rmutation rescues ac-
tivity, we performed protease activity assays complemented by
molecular dynamics simulations, which showed that protease-
peptide interactions far outside the targeted peptide cleavage
sites mediate substrate recognition by NS3-4A and support pro-
tease cleavage kinetics. These interactions shed new light on the
mechanisms by which NS3-4A cleaves its substrates, viral poly-
proteins and a prime cellular antiviral adaptor protein, the mi-
tochondrial antiviral signaling protein MAVS. Peptide binding
is mediated by an extended hydrogen-bond network in NS3-4A
that was effectively optimized for protease-MAVS binding in
Asp168 variants with rescued replicative fitness fromNS3-Q41R.
In the protease harboring NS3-Q41R, the N-terminal cleavage
products of MAVS retained high affinity to the active site, ren-
dering the protease susceptible for potential product inhibition.
Our findings reveal delicately balanced protease-peptide inter-
actions in viral replication and immune escape that likely
restrict the protease adaptive capability and narrow the virus ev-
olutionary space.
Viruses under treatment with specific antivirals undergo
rapid adaptive selection to maximize their fit for escape from
drug pressure. Thereby, increased replicative fitness can lead to
decreased drug sensitivity of viral variants (1) and determine
the probability with which resistant variants will persist (2).
Based on a deterministic model (3–6), hepatitis C virus (HCV)
variants under selective pressure with direct-acting antiviral
agents are selected by their degree of resistance and capability
to replicate and assemble infectious virus particles (7). Protease
inhibitors (PI) against the serine protease NS3-4A of HCV are
burdened with a particularly high risk for drug resistance devel-
opment that inflicts considerable fitness costs (7, 8). Although
compensatory second-site mutations that rescue fitness deficits
from drug resistance mutations are pivotal drivers of viral qua-
sispecies evolution (3, 9, 10), they are virtually not observed
upon PI treatment failure in the NS3-4A protease of HCV.
Although the impact of mutations on PI resistance has been
well-characterized, their role in replicative fitness of viral var-
iants is less understood. TheNS3-4A protease plays an essential
role in the HCV replication cycle (11–13). In particular, NS3-
4A is involved in RNA synthesis by proteolytically processing
nonstructural proteins from the viral polyprotein. In addition,
the capacity to cleave and inactivate mitochondrial antiviral
signaling protein (MAVS) (13) (also called Cardif, VISA, and
IPS-1 (14–16)) in the RIG-I-signaling pathway is a cardinal fea-
ture of NS3-4A, by which HCV blocks induction of IFN-b.
MAVS cleavage is a key mechanism in the selection of drug-re-
sistance mutations against macrocyclic PIs and is important for
promoting viral persistence. Novel PI-based treatment regi-
mens still appear to fail in some patients, specifically those with
advanced liver disease or liver cirrhosis (17). Importantly, most
of these difficult-to-treat patients show dominant resistant var-
iants with D168A or D168V amino acid substitutions in NS3-
4A at the time of virologic failure (17). We previously showed
that theAsp168mutant proteases are characterized by increased
capacity to cleave MAVS and suppress IFN-b induction (18).
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The reconstitution of a tight network of electrostatic interac-
tions between protease and the peptide substrate in those var-
iants allowsmuch stronger binding ofMAVS than in other pro-
tease variants orWTHCV (18).
In the present study, we unraveled a molecular mechanism
in PI-resistant Asp168 variants that affect the cutting efficiency
of peptide substrates by a second-site mutation in the viral pro-
tease, NS3-Q41R. By interference with critically balanced pro-
tease-peptide interactions, the second-site mutation rescues
replicative fitness deficits of Asp168 variants in infectious cell
culture. The finding that NS3-Q41R, which itself is reported
to confer resistance to macrocyclic PIs (19), has a fitness-
compensatory effect in Asp168 variants is surprising, given
the very low prevalence of variants harboring Q41R in PI-
experienced patients (,0.1%) (20). Our findings highlight a
previously unknown molecular mechanism for MAVS that
potentially restricts virus evolution under PI pressure, pro-
viding a new paradigm for variant selection from HCV-
infected cells.
Results
Rational approach to characterize replicative fitness of
PI-resistant variants
We aimed to identify PI resistance–associated amino acid sub-
stitutions in NS3-4A that lead to high replicative fitness and
potentially confer a general drug resistance phenotype to the vi-
rus (1). Resistance mutations were identified by a review of pub-
lished data from both cell culture–based and clinical studies of
PIs (7).
Replicative fitness of Asp168 variants is enhanced by the
second-site mutation NS3-Q41R
To characterize the impact of PI-resistance mutations on
RNA replication, we constructed two comprehensive panels,
each with 23 resistance mutations in derivatives of pH77S (21)
(Fig. 1,A andB). The two panels only differed by the cell culture
adaptive mutation Q41R in their NS3-4A protease backbone
(7) (Fig. 1B). We measured Gaussia luciferase (GLuc) activity
from NS3-Gln41/GLuc2A RNA and NS3-Q41R/GLuc2A RNA
in media collected at 24-h intervals after transfection. NS3-
Q41R showed no loss of replication capacity compared with
NS3-Gln41, although the replication capacity of mutants in
both backbones, in general, was more compromised in NS3-
Q41R (Fig. 1C). Interestingly, NS3-Q41R served to promote the
replication of theNS3–Asp168 variants Ala/Glu/His/Val despite
acting synergistically to impair the replication of other key PI-
resistant variants, such as R155K. Compared with WT, the
GLuc activity of D168A was compensated to ;91% by NS3-
Q41R (161% increase compared with NS3-Gln41; fold change
(FC) 2.6) and that in D168E was boosted to ;141% by NS3-
Q41R (44% increase compared with NS3-Gln41; FC 1.4). For
the clinically relevant D168A/Emutants with increased replica-
tive fitness by NS3-Q41R, we further measured the ability to
produce infectious viruses in NS3-Gln41 and NS3-Q41R prote-
ase backbones using a sensitive GLuc assay (Fig. 2). Both
mutants produced more infectious viruses in the NS3-Q41R
backbone than in NS3-Gln41, which corresponded with the re-
spective results on their RNA replication capacity (Fig. 2).
Asp168 mutants are signature mutations selected from pressure
with macrocyclic PIs such as simeprevir, asunaprevir, paritap-
revir and glecaprevir (17, 22). To assess the ability of a macrocy-
clic PI to inhibit the RNA replication of PI-resistant variants in
NS3-Gln41 and NS3-Q41R protease backbones, antiviral EC50
values were determined from the concentration of simeprevir
required to cause a 50% reduction in the secretion of GLuc by
RNA-transfected cells. The NS3-Q41R backbone caused an
increase in EC50 for most PI-resistance mutations tested with
on-average-higher–level PI resistance than the respective
mutants in an NS3-Gln41 genomic background. All Asp168
mutants tested in the NS3-Q41R backbone showed high-level
PI resistance against simeprevir (FC 32–156 compared with the
WT protease NS3-Gln41); see Table 1 and Fig. S1 for details on
the replicative fitness and drug resistance.
For further in vitro characterization, we selected the clini-
cally most relevant PI-resistance–associated mutations
D168A and D168E that showed rescued replicative fitness
due to NS3-Q41R, but omitted D168H (clinically less
important) and D168V (only weak fitness compensation).
D168T was selected from the Asp168 mutants as a negative
control without impact on replicative fitness in protease
backbones6Q41R.
NS3-Q41R had no effect on the protease fold
To characterize the fitness-compensatory mechanism of
NS3-Q41R in Asp168 variants, we expressed and purified the
NS3-4A WT fusion and different mutant forms (see “Experi-
mental procedures” and Fig. S2). We first tested if D168A/E/T6
NS3-Q41R had an effect on the protease stability (Fig. 3 and
Table 2). The impact of mutants on protein-folding was deter-
mined by a thermal shift assay, where protein denaturation at
increasing temperatures was revealed by increased fluores-
cence (see “Experimental procedures”). The NS3-Gln41 prote-
ase WT was stable to temperature with a melting temperature,
Tm, at 54.9 °C (Fig. 3). NS3-Q41R had no effect on the protein
stability. A significant difference in protein stability was
observed between D168E and D168A/Tmutant proteases irre-
spective of the NS3-4A protease background 6 Q41R (p ,
0.0001) (Fig. 3). As we showed previously (18), the impact on
protein fold in Asp168 mutants is likely related to weakening or
stabilization of a local salt bridge and H-bond network in the
outer ligand-binding site of the protease. In contrast to
D168A, the D168E mutant can compensate the missing inter-
actions of the Asp168 residue with Arg155 and Arg123 and stabi-
lize the protein fold (18). Our present study confirms the
modeling results published earlier (18). The melting tempera-
tures reflect a stable protease fold in D168E versus destabili-
zation in D168A (Fig. 3). Importantly, NS3-Q41R showed no
difference to the NS3-Gln41WT background either as a single
mutant or as a second-site mutation with D168A/E/T (Fig. 3
and Table 2). Thus, we considered it unlikely that the
increased replicative fitness in the NS3-Q41R background in
D168A/E could be due to a modulation of protein stability in
the NS3-4A protease.
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Figure 1. Replicative fitness of PI-resistant variants in NS3 6 Q41R protease genomic backgrounds. A, structural context of PI-resistance mutations
depicted on the NS3-4A protease structure from PDB 2OC8 (50) with PI bound to the ligand-binding site (purple stick model); ligand-binding pockets S4 to S19
(51). The protein surface is partially transparent; protease domain: green, NS4A: light blue. Gln41 and Asp168 are shown as blue stick models located at opposite
ends of the protease substrate–binding pocket. B, the H77S.2molecular clone contains six cell culture adaptivemutations (not shown) throughout the viral ge-
nome; the only cell culture adaptive mutation located in the NS3-4A protease domain, NS3-Q41R (depicted by arrow), is reverted back to NS3-Gln41 WT in
H77S.3 (6). C, GLuc activity secreted by RNA-transfected cells normalized to pH77S.3 and pH77S.2 WT. Blue shading indicates PI-resistant variants with
enhanced replicative fitness by NS3-Q41R. Data shown represent the mean6 S.D. from at least three independent experiments; *p, 0.001; **p, 0.0001; by
two-sided t test. AAG, negative control.
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NS3-Q41R can modulate the kinetic properties of the
protease for viral polyprotein substrates and MAVS
Next, we analyzed the protease enzymatic activity using an in
vitro FRET-based assay that measures the cleavage of a viral
polyprotein substrate. We tested the kinetic properties of NS3-
Gln41 WT and D168A/E/T6 NS3-Q41R mutants using a pep-
tide substrate derived from the viral NS4A/4B polyprotein
cleavage site (Fig. 4A and Table 2) comprising an excited donor
molecule and a quencher (see “Experimental procedures”). In
this assay, fluorescence is released when the protease recog-
nizes and cleaves the FRET substrate. We determined the
amount of substrate needed to obtain half of the proteasemaxi-
mum rate of reaction (Km) and substrate turnover rates (kcat).
The protease with the NS3-Q41R backbone exhibited a lower
Km than the NS3-Gln
41 WT (p = 0.08; FC 0.5). No difference
was found in the substrate turnover kcat between the two
genomic backgrounds. The D168A mutant in NS3-Gln41
showed a significantly lower kcat (p = 0.0008; FC 1.1) and a
slight decrease in Km (p = 0.24; FC 0.3) compared with Asp
168-
WT. A further decrease in Km (p = 0.13; FC 0.8) paralleled by a
significant increase in kcat (p = 0.003; FC 0.7) for D168A was
found in the NS3-Q41R backbone. Whereas differences in Km
were not significant for D168E 6 NS3-Q41R, kcat was signifi-
cantly higher for D168E in the NS3-Q41R versus NS3-Gln41
backbone (p = 0.01; FC 0.2) (Fig. 4A). No such effect was
observed for D168T 6 NS3-Q41R (Fig. 4A), which was tested
as a Asp168 variant not compensated for replicative fitness defi-
cits by NS3-Q41R (Fig. 1C). Although Km and kcat varied in
rather narrow ranges between 1.7 and 3.1 mM and 0.09 and 0.19,
respectively, the kinetic constants reflect the fitness-compensa-
tory effect of NS3-Q41R for D168A/E variants that we observed
in infectious cell culture (Fig. 1C).
Notably, NS3-Q41R is not observed as a fitness-compensa-
tory mutation in PI-failure patients with Asp168 variants (23).
As we showed previously, efficient MAVS cleavage is a charac-
teristic feature of Asp168 variants and a key escape mechanism
under selective pressure with macrocyclic PIs (18). Hence, we
reasoned that NS3-Q41R could have varied the kinetic proper-
ties of D168A variants toward MAVS. To characterize the
effect of D168A and NS3-Q41R on the protease-MAVS cleav-
age kinetics, we designed a novel FRET peptide incorporating
the MAVS cleavage site. As done for NS4A/4B, Km and kcat of
D168A 6 NS3-Q41R were determined for the MAVS peptide
(Fig. 4B). In contrast to NS4A/4B, we observed vast variations
in the kinetic constants for MAVS. Compared with the NS3-
Gln41 protease WT, NS3-Q41R showed an;5-fold increase in
kcat (p = 0.008; FC 4.7), although theKmwas significantly higher
than in theWT (p = 0.02; FC 4.8). A highly significant and fun-
damental change with inverse kinetic constants was observed
when NS3-Q41R was present as a second-site mutation in the
D168A protease (Fig. 4B). Here, D168A showed a more than
16-fold increase in kcat compared with D168A without NS3-
Q41R (p = 0.0003; FC 16.5). In parallel, the Kmwas significantly
decreased (p, 0.05; FC 7.1) (Fig. 4B). Thus, there was large re-
versal in Km and kcat for D168A upon the addition of NS3-
Q41R. Next, we calculated the ratio kcat/Km, the specificity con-
stant, to compare the relative rates of NS3-4A protease cleavage
Figure 2. Impact of NS3 6 Q41R on the infectious virus production of Asp168 variants. Comparison of infectious virus yield from D168A/E-protease
mutants within NS3-Gln41 and NS3-Q41R backbones. Infectious virus production determined from supernatant fluids at 72 and 96 h infected to naïve Huh-7.5
cells as determined by GLuc activity assay. Data shown represent themean6 S.D. from at least three independent experiments.
Table 1
HCV RNA replication and EC50 of simeprevir for PI-resistant variants
HCV RNA replication and EC50 of simeprevir for PI-resistant variants in an NS3-
Gln41 (H77S.3) or NS3-Q41R (H77S.2) genomic background.
Residue Variant
Replication capacity (%*) EC50 (nM
§)
NS3-Q41R NS3-Q41 NS3-Q41R NS3-Q41
WT 100 100 6.4, 0.3 6.4, 0.3
V36 A 50.4 89.7 56, 3.5 14, 6.2
G 2.6 20.8 n/a 42, 5.2
L 76.7 100.8 38, 2.6 12, 2.0
M 27.8 94.7 37, 2.6 11, 1.3
Q41 R# n/a 99.9 29, 0.4 29, 0.4
F43 S 3.2 70.2 197, 24 67, 3.2
T54 A 14.5 68.0 7.3, 0.2 3.2, 0.6
Q80 R 24.1 51.4 239, 16 48, 5.3
S138 T 1.4 0.2 185, 35 n/a
R155 K 23.2 47.1 .1000 259, 8.8
T 4.6 71.1 162, 21 85, 3.7
G 2.7 45.8 n/a 74, 5.7
W 2.5 28.1 n/a 544, 20
A156 G 41.7 45.8 329, 26 84, 7.7
S 62.5 50.9 5.8, 1.0 2.1, 1.0
T 0.88 2.5 n/a 270, 21
V 1.0 0.3 n/a n/a
D168 A 90.5 34.7 .1000 2047, 270
E 141.0 97.9 504, 65 120, 4.8
H 80.0 55.4 .1000 2228, 103
I 20.1 43.7 .1000 6935, 469
T 84.7 97.9 .1000 2025, 77
V 62.5 47.0 .1000 8070, 624
Y 55.4 54.2 n/d 2640, 584
*Replication capacity relative toWT (%).
§EC50 (nM; mean, S.D.)
#H77S.2 is Arg41 and H77S.3 is Gln41
n/a, replication too low to measure EC50; n/d, mutant not prepared.
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on the competing substrates NS4A/4B and MAVS (Table 2).
We found that the specificity constant of the D168A-protease
for MAVS increased more than 100-fold when harboring NS3-
Q41R and 3.3-fold higher than for NS4A/4B.
NS3-Q41R increases the ability of the protease and Asp168
variants to cleave MAVS
The above results using peptide substrates in vitro suggested
a fitness advantage due to NS3-Q41R in Asp168 variants via
increased MAVS cleavage capacity. To test this hypothesis in
cells, we prepared expressed constructs for Asp168-WT and
D168A/E/Tmutants in protease genomic backgrounds6NS3-
Q41R. The expressed constructs were transfected into human
bone osteosarcoma epithelial cell line U-2 OS cells that express
high levels of endogenous MAVS (18). Western blotting was
employed after transfection with NS3-4A expression con-
structs to detect full-length and cleaved MAVS (Fig. 5A). Our
data revealed that NS3-Gln41 constructs harboring D168E/T
had a comparable capacity to cleave endogenous MAVS com-
pared with the NS3-Gln41 protease WT. A notable exception is
D168A in the NS3-Gln41 protease that displayed a significantly
higher potency to cleave MAVS than the NS3-Gln41 protease
WT, which is in line with our previous findings (18). Interest-
ingly, the addition of NS3-Q41R increased the capacity of the
protease to cleaveMAVS for all Asp168 variants tested (Fig. 5A).
Most notably, full-length MAVS was not visible already after
12 h of transfection in D168A1NS3-Q41R.We observed com-
plete cleavage of MAVS after 16 h of transfection for D168A/E/
T in the NS3-Q41R background. Remarkably, we observed no
degradation of the cleavage products for D168A/E/T in NS3-
Q41R after 12 h of transfection (Fig. 5A).
Next, we tested the capacity of MAVS in U-2 OS cells to
induce IFN-b for Asp168-WT and D168A/E/T mutants in pro-
tease genomic backgrounds 6 NS3-Q41R after transfection
with an IFN-b–reporter plasmid (Fig. 5B). As expected, over-
expression of MAVS resulted in strong activation of the IFN-b
reporter. As previously shown (18), we found IFN-b activity
significantly inhibited by D168A in the NS3-Gln41 protease
backbone. Moreover, we found that proteases harboring NS3-
Q41R or NS3-Q41R1D168E significantly attenuated the IFN-
Figure 3. Impact of Asp168 mutants on the protein fold of the NS3-4A protease6 NS3-Q41R. Data from real-time thermal stability assay using Sypro Or-
ange, a temperature-stable fluorophore that exhibits enhanced fluorescence upon interacting with unfolded proteins. The thermal stability of WT protease
andmutants was assessed under increasing incubation temperatures. The impact of mutations on protein unfolding patterns is characterized by fluorescence
emission curves (left). Melting temperatures (Tm) from purified NS3-4A protease mutants are determined by fitting the sigmoidal melt curve to the Boltzmann
equation (right). Error bars represent themean6 S.D. from at least three independent experiments; *p 0.05; **p 0.01; by two-sided t test.
Table 2
Enzyme kinetic constants and protein melting temperatures for NS3-4A protease variants
Kinetic constants (left panel) and melting temperatures (right panel) were obtained by a FRET-based protease and thermal shift assay, respectively. Data shown represent





Tm (°C)Km (mM) kcat (/s) kcat/Km (1/(s*mM))
NS4A/4B WT (Q41) 3.116 0.29 0.196 0.011 0.0626 0.008 WT (Q41) 54.96 0.3
Q41R 2.116 0.14 0.186 0.006 0.0856 0.008 Q41R 55.16 0.3
D168A 2.456 0.23 0.096 0.004 0.0356 0.004 D168A 48.76 0.1
Q41R-D168A 1.716 0.23 0.156 0.009 0.0876 0.015 Q41R-D168A 48.36 0.2
D168E 1.796 0.11 0.126 0.003 0.0676 0.005 D168E 55.96 0.2
Q41R-D168E 1.836 0.10 0.146 0.001 0.0746 0.005 Q41R-D168E 55.86 0.3
D168T 2.036 0.15 0.136 0.005 0.0646 0.006 D168T 47.16 0.1
Q41R-D168T 1.696 0.14 0.126 0.004 0.0716 0.007 Q41R-D168T 48.56 0.2
MAVS WT (Q41) 7.826 0.70 0.0586 0.002 0.0086 0.001
Q41R 37.326 4.42 0.2756 0.021 0.0076 0.001
D168A 14.416 2.91 0.0296 0.003 0.0026 0.000
Q41R-D168A 1.776 0.14 0.5076 0.011 0.2876 0.024
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b activity. The competence of the Q41R-D168A protease to
interfere with MAVS-induced IFN-b–reporter activation did
not differ significantly from the Gln41 background. A potential
explanation is that peptides fromMAVS cleavage could play an
inhibitory role at the protease active site. Such a model could
explain that the Q41R-D168A protease with high kcat but
low Km for MAVS was not superior in inhibiting IFN-b ac-
tivity compared with the D168A mutant protease (Fig. 4B
and Fig. 5B).
An extended hydrogen-bond network around the protease
active site plays a critical role in substrate recognition
We previously showed that the mutant D168A reconstitutes
electrostatic interactions between the protease and MAVS,
facilitating stronger binding of the MAVS peptide to the
D168A mutant than to the Asp168-WT protease (18). To char-
acterize the molecular mechanisms of fitness compensation by
NS3-Q41R as a second-site mutation in the D168A protease,
we performed molecular dynamics (MD) simulations of the
NS3-Gln41 protease WT and the Q41R-D168A mutant prote-
ase, bound to the viral polyprotein junction NS4A/4B or to
MAVS (Fig. 6, left panel). For each simulation, we analyzed the
H-bond network surrounding the protease active center (Fig. 6,
right panel) and calculated peptide-protease interaction ener-
gies (Table 3).
A comparison of the simulated systems showed that the
Asp168-WT protease with NS3-Gln41 bound to NS4A/4B
formed a well-balanced and stable extended H-bond network
(Fig. 6,A and B). The core of this network consisted of H-bonds
within the protease catalytic triad Asp81-His57-Ser139. This core
network was extended by H-bond contacts to Gln41 and
Arg155-Asp168-Arg123. The twomutants D168A and NS3-Q41R
substantially disturbed this extended network, weakening its
coupling to the protease active site (Fig. 6, C and D). Instead,
Arg41 and Arg123 participated in more H-bonds (;1.3 more)
and p–p contacts (142% of simulation time) to the NS4A/4B
peptide substrate than in the WT protease. For the Q41R-
D168Amutant protease, the interaction energy between prote-
ase and the NS4A/4B noncleaved substrate increased by;29%
compared with theWT protease (Table 3).
A similar analysis of the H-bond network for the WT prote-
ase bound to MAVS identified a substantially weaker stabiliza-
tion of the catalytic site (Fig. 6, E and F) than in the NS4A/4B-
protease complex (Fig. 6, A and B). The destabilization was a
direct consequence of polar MAVS residues competing with
intraprotease H-bonds within the extended network. This
changed considerably because of the mutants D168A and NS3-
Q41R (Fig. 6, G and H). Q41R participated in strong H-bonds
(10.98) with the protease active site while establishing p–p
interactions (181%) to MAVS at the same time, rigidifying the
complex around the active site (Fig. 6H). In addition, D168A
gained strong H-bonds between MAVS and Arg155 (11.31)/
Arg123 (10.21). These changes in the bonding network lever-
aged the affinity of the N-terminal MAVS and NS4A/4B cleav-
age products to the Q41R-D168A protease (77% versus 9% gain
in protease-peptide interaction energy, respectively) (Table 3).
Summing up effects from protease mutations and substrate
binding, NS3-Q41R and D168A showed substantial impact on
the H-bond network at the protease active site. Both mutations
split the H-bond network and freed protease residues for
Figure 4. Impact of Asp168 mutants and NS3 6 Q41R on protease enzymatic function. A, reaction velocity and Michealis-Menten kinetics as assessed
from purified protein of protease WT and Asp168 mutants6 NS3-Q41R and the natural polyprotein substrate NS4A/4B and (B) assessed for the MAVS peptide
(each at different peptide concentrations). Reaction constants Km and kcat were calculated after nonlinear regression curve fitting. Error bars represent the
mean6 S.D. from at least three independent experiments; *p, 0.05; **p 0.01; ***p 0.001; by two-sided t test.
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additional interactions with the substrates, explaining the
observed decreases in Km values. Binding of the natural sub-
strate NS4A/4B yielded a stable extended H-bond network in
the WT protease, which was weakened by NS3-Q41R and
D168A. In contrast, MAVS binding to the protease naturally
disturbed this network in theWT protease. Here, the PI-resist-
ance mutation D168A and its second-site mutation NS3-Q41R
showed unique compensatory interactions in the protease
bound to MAVS and stabilization of the protease active site
surroundings. This aligns well with the kcat trends from our
enzyme activity assays andMichaelis-Menten kinetics (Fig. 4).
Discussion
Fitness compensation by a second-site mutation in the HCV
protease NS3-4A, as we show here, has not been noted previ-
ously (20, 23). We find NS3-Q41R to permit a fitness recovery
for viral variants with resistance-associated amino acid substi-
tutions at Asp168 in infectious cell culture at high-level resist-
ance against a macrocyclic PI (Fig. 1C and Table 1). Our
findings emphasize the capability of NS3-Q41R to yield “super-
fit” PI-resistant Asp168 variants. However, NS3-Q41R is not
observed in patients, though the selection of Asp168 variants in
advanced-stage liver disease is responsible for the vast majority
of PI treatment failures (17). We considered the underlying
mechanisms to be important to understand structural con-
straints and adaptive capability in HCVNS3-4A.
To characterize the molecular mechanism of fitness com-
pensation by NS3-Q41R, we used enzyme kinetics from
purified protein and complementary molecular dynamics
simulations. As previously shown, a characteristic feature of
Asp168-protease mutants is the molecular adaptation of the
protease active site for cleavage and inactivation of MAVS (18),
a key cellular antiviral adaptor protein whose expression level
directly determines antiviral immunity (14–16, 24). Strikingly,
we found that the D168A mutant protease boosted to 16-fold
higher MAVS cleavage efficiency by NS3-Q41R, whereas the
efficiency for the viral polyprotein substrate was only 2-fold
increased (Fig. 4). This is important, given that blocking RIG-I
signaling by targeting MAVS is a key strategy in several highly
diverse classes of viruses to evade type I–interferon immune
responses (25–27). Conversely, MAVS in primates evolved
Figure 5. Impact of Asp168 mutants and NS36 Q41R on MAVS cleavage capacity and IFN-b activation. A, U-2 OS cells were left untransfected (mock),
transfected with a GFP expression plasmid (control of transfection efficiency), and transfected with expression constructs harboring NS3-Gln41 or NS3-Q41R6
D168A/E/T. MAVS cleavage as assessed byWestern blotting; one of five representative experiments is shown. B, U-2 OS cells co-transfectedwith IFN-b reporter
plasmids, a full-lengthMAVS expression construct, and D168A/E/Tmutant protease constructs6NS3-Q41R, subsequently analyzed for IFN-b-dependent lucif-
erase activity. Renilla luciferase (RLuc) activity determined to normalized IFN-b activity. Error bars represent the mean6 S.D. from at least three independent
experiments; *p 0.05; **p 0.01; by two-sided t test; f.l., full-length; cl., cleaved form; FI, fold induction; ns, not significant.
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under strong positive selection, driven by antagonism from an-
cient “paleovirus” infections (28). As a consequence of prote-
ase-peptide coevolution, viral proteases can be highly adapted
for MAVS cleavage already in theWT protein (28). In the HCV
protease NS3-4A, we found that NS3-Q41R had a strong
impact on the catalytic activity and turnover in Asp168 mutant
proteases, thereby differentially tuning the protease for viral
polyprotein substrates and MAVS. Of note, the changes in the
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protease kinetic constants for the viral polyprotein substrate
NS4A/4B reflect the fitness-compensatory effect of NS3-Q41R
that we observed in infectious cell culture. The hepatocyte-
derived cellular carcinoma cell line Huh-7.5 cells that we were
using here are defective for signaling via RIG-I andMAVS (29).
Hence, the MAVS cleavage capacity of the protease mutants
should not have made an impact on the replicative fitness in
our cell culture model of HCV infection.
Mechanistically, we find a delicately balanced extended
hydrogen-bond network around the protease active site that
was altered by Asp168 mutants and the second-site mutation
NS3-Q41R. Governed by changes on the opposite ends of this
network (Fig. 6), the protease active site environment is effec-
tively optimized for MAVS binding by D168A and NS3-Q41R
(Fig. 6H and Table 3). In line with these findings, we show that
NS3-Q41R in cell culture shifted the balance in protease-sub-
strate recognition in the Asp168 variants toward MAVS (Fig. 5).
The presence of hydrophilic and charged residues in the pep-
tide substrate between the P4 and P39 sites is likely a key factor
determining how Asp168 and Gln41 mutations influence bind-
ing and catalysis. Therefore, based on our observations for
NS4A/4B andMAVS, the binding of other cellular substrates of
the NS3-4A protease might also be affected by mutation of
these sites: Primarily hydrophobic substrates like the mem-
brane-associated glutathione peroxidase 8, the E3 ubiquitin
ligase component UV-damaged DNA-binding protein 1, and
the cleavage site bwithin T-cell protein tyrosine phosphatase, a
phosphatase involved in growth factor signaling, could behave
similarly to NS4A/4B, whereas hydrophilic residues of the Toll/
interleukin-1 receptor domain–containing adaptor inducing
interferon-b or the T-cell protein tyrosine phosphatase cleav-
age site a might interact with the extended network along the
lines ofMAVS (Fig. S3).
Notably, we found that the MAVS-cleaved products did not
get degraded quickly and retained high affinity to Asp168 prote-
ase variants when harboring NS3-Q41R (Fig. 5 and Table 3).
Hence, we speculated that the cleaved products might compete
with protease substrates at the active site, a mechanism that
potentially could down-regulate the protease catalytic effi-
ciency. Adding to this notion, we calculated protease-peptide
interaction energy differences from the molecular dynamics
simulations that in the Q41R-D168A mutant context showed a
remarkable gain of 77% for the N-terminal MAVS cleavage
product compared with only 9% for the viral polyprotein pep-
tide (Table 3). In support of a direct impact of MAVS on the
protease catalytic activity, preincubation of the purified protein
with MAVS peptides showed a more potent blockade of
enzyme activity in a protease harboring NS3-Q41R than in the
WT protease (Fig. 7).
It is difficult to compare directly the in vitro biochemistry
with the cellular degradation of MAVS. There are several
strong limitations for this comparison, such as ambiguous con-
centrations of viral protease, polyprotein substrates, and
MAVS expression levels in cells. However, from the biochemis-
try data, we clearly conclude that mutations in the NS3-4A pro-
tease can have vast differences in the cutting efficiency of pep-
tide substrates. Our data suggest that protease variants already
optimized for MAVS cleavage can be easily overfitted for this
peptide substrate by second-site mutations in NS3-4A. Such a
mechanism could interfere with RNA synthesis and immune
Figure 7. Inhibition of the NS3-4A protease6 Q41R by MAVS cleavage
products. Relative reaction velocity for NS4A/4B cleavage as assessed for the
purified NS3-Gln41 protease WT and NS3-Q41R mutant protease (measured
by FRET protease assay) and different preincubation time with MAVS peptide
(0, 10, and 20 min). Reference velocity (100%) is the cleavage reaction for the
NS4A/4B FRET peptide without MAVS. Error bars represent the mean 6 S.D.
from at least three independent experiments; ns, not significant, p = 0.01; by
two-sided t test.
Figure 6. Molecular characterization of protease-substrate interactions. Illustrations of representative protease binding-site conformations (left panel: A,
C, E and G) and H-bond networks of protease-substrate complex simulations (right panel: B, D, F and H). (A) 3D structure and (B) residue-interaction network of
the NS4A/4B substrate bound to the NS3-Gln41 protease WT or (C) 3D structure and (D) residue-interaction network for NS4A/4B bound to the Q41R-D168A
protease; (E) 3D structure and (F) residue-interaction network for MAVS bound to the NS3-Gln41 protease WT or (G) 3D structure and (H) residue-interaction
network for MAVS bound to the Q41R-D168A protease. Hydrogen bonds present in each time frame were extracted fromMD trajectories. Edge widths (single
lines) in the residue networks shown represent the average number of H-bonds during simulation time and correspond to the individual bond strength; a
quantitative measure for the bond strength was provided by corresponding numbers. Only edges above a minimum occurrence limit of 0.1 are shown. Cat-
ion-p stacking interactions between arginine and histidine residues (time fraction withinp stacking distance cutoff) are shown as double lines with caps. Atom
colors: Substrate (green); protease catalytic triad (red); extended H-bond network of the catalytic triad (blue). H-bonds are shown inmagenta (A, C, E and G) and
black (B,D, F andH).
Table 3
Average interaction energies of the NS3-4A protease-substrate
complexes
Average interaction energies in kcal/mol from the last 100 ns of MD simulations
of the NS3-4A protease-substrate complexes.
Variant Substrate DEb DDEc se(DE)
d
WT (Q41) NS4A/4B 2558.85 23% 8.34
N-term NS4A/4Ba 2541.94 3.79
Q41R-D168A NS4A/4B 2719.46 19% 11.33
N-term NS4A/4Ba 2783.06 7.80
WT (Q41) MAVS 2184.57 149% 6.16
N-termMAVSa 2274.70 6.22
Q41R-D168A MAVS 2237.56 177% 4.22
N-termMAVSa 2420.34 3.29
aN-terminal cleavage product.
bAverage interaction energy without solvent.
cRelative interaction energy difference of the Q41R-D168A mutant compared with
WT.
dError of uncorrelated samples.
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escape and hence prevent selection of fitness-compensatory
mutations such as NS3-Q41R in patients. The mechanism
could potentially explain previous observations from a chim-
panzee infected with a cell culture–derived virus containing
NS3-Q41R that initially was poorly fit but evolved to establish
long-term persistent infection (30). Yi and coworkers observed
an unusual 4–6-week delay before detectable viremia in this
animal, during which the level of intrahepatic innate immune
responses increased substantially. They found that the cell cul-
ture–adapted H77S.2 strain had reverted Arg41 back to Gln41
WT before viremia (30), whereas other chimpanzees infected
by NS3-Gln41WT strains were viremic within a week (31, 32).
Collectively, our data support a model in which balancing
between MAVS cleavage capability and efficiency of polypro-
tein processing likely restricts the selection of drug-resistant
HCV protease variants in vivo. Our data suggest that the nega-
tive selection of fitness-compensatory mutations in NS3-4A to
some extent is a consequence of protease-MAVS overfitting,
which is important because it can prevent fitness compensation
and hence ultimately contribute to extinction of PI-resistant
HCV variants upon treatment failure (2–5).
Experimental procedures
Cell culture studies
Central to our studies has been the use of an infectious mo-
lecular clone of genotype 1a H77 virus (21). The clone pH77S.2
was derived from pH77S and differs from pH77S.3 by the cell
culture adaptive mutation NS3-Q41R in the NS3-4A protease
domain (Fig. 1B). When transfected into permissive Huh-7.5
cells (21), genome-length RNA transcribed from pH77S.2 and
pH77S.3 replicates efficiently and produces a virus that is infec-
tious in naïve cells (21). To monitor replication, the GLuc
sequence, fused at its C terminus to the foot-and-mouth disease
virus 2A autoprotease, was inserted between p7 andNS2 (7).
Site-directed mutagenesis and transfection
Primers for NS3-4A amplification were used with restriction




ATCTCATCGAACTC). Amplified PCR products were
subcloned into the expression vector pcDNA3.1(1) from Invi-
trogen. NS3-4A mutant constructs in NS3-Gln41 and NS3-
Q41R backbones were generated by site-directed mutagenesis.
Primers for the mutagenesis of Asp168 mutants were designed
as follows: GT1a-NS3-D168A-For (GCTAAAGCGGTGGCC-





TATCCCTGTG) and GT1a-NS3-D168T-Rev (CACAGG-
GATAAAGGTCACCGCTTTAGC). All generated constructs
were controlled by sequencing with Eurofins. Transfection was
performed using the X-tremeGene HPDNA transfection reagent
(Roche) according to themanufacturer’s instructions.
Viral fitness and antiviral resistance
Genome-length RNA was transcribed from the mutated
pH77S.2, pH77S.3, pH77S.2/Gluc2A, and pH77S.3/GLuc2A
plasmids in vitro, and studies to assess antiviral resistance and
viral fitness were carried out as described previously (7).
MAVS cleavage and IFN-b promoter activation
To assess MAVS cleavage in cells, we used U-2 OS human
osteosarcoma cells (obtained from the American Type Culture
Collection) and Western blotting. U-2 OS cells express high
levels of endogenous MAVS and are highly permissive for
transfection with NS3-4A expression constructs as previously
described (18). IFN-b promoter activation assays were based
on luciferase reporter assays as described previously (33).
Antibodies
Western blot analyses were performed using the following
antibodies: mouse mAb to Cardif/MAVS (Adri-1) (catalog no.
A3002702, AdipoGen), anti-b-actin mouse mAb (AC-15)
(Sigma-Aldrich), and goat antibody to HCV NS3 region (cata-
log no. 8C07014,Meridian Life Science).
Protein biochemistry
For transformation and recombinant NS3-4A protein expres-
sion, the pET-15b vector incorporating the single-chain proteo-
lytic domain (NS4A21-32-GSGS-NS33-181) (34) ofWT andmutant
NS3-4A was transformed into Escherichia coli Rosetta (DE3)
pLysS competent cells (Novagen) according to the manufac-
turer’s protocol. Recombinant protein production and purifica-
tion was carried out as described previously (Fig. S2) (34).
Thermal shift assay
Stability of the protein fold of expressed WT and mutant
NS3-4Awas measured by fluorescence-based thermal shift (35)
using Sypro Orange, a temperature-stable fluorophore that
exhibits enhanced fluorescence upon interacting with unfolded
proteins. The impact of mutations on protein unfolding pat-
terns is characterized by fluorescence emission curves. Melting
temperatures from purified NS3-4A protease mutants are
determined by fitting the sigmoidal melt curve to the Boltz-
mann equation.
Protease activity assay
The enzymatic activity and Michaelis-Menten kinetics of
WT andmutant NS3-4A proteases were measured by a fluores-
cence-based protease assay (36, 37). To measure peptide cleav-
age kinetics, a viral polyprotein substrate derived from the
NS4A/4B cleavage site was purchased from Anaspec (SensoLyte
520 HCV). To determine enzyme kinetics for MAVS cleavage,
we designed a novel FRET peptide incorporating the MAVS
cleavage site, produced byAnaspec (Ac–EREVPCHRPS–NH2).
MAVS product inhibition assay
We used an untagged MAVS peptide incorporating the
MAVS cleavage site (Ac–EREVPCHRPS–NH2) to determine
the influence of MAVS cleavage products on the cleavage
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kinetics of viral polyprotein substrates. Small amounts of puri-
fied NS3-4A protease (NS3-Gln41 WT or NS3-Q41R, 50 nM)
were preincubated with MAVS peptide (50 mM) for 0, 10, or 20
min at room temperature to allow different time spans for
cleavage product formation. After preincubation, 2 mM of the
NS4A/4B FRET peptide (SensoLyte 520 HCV, Anaspec) was
added and reaction velocity was measured as described above.
Of note, MAVS andNS3-4A are shown to colocalize in infected
cells (38). Hence, the effective concentration of MAVS can the-
oretically reach levels higher than 50 mM.
Statistical analyses
Comparisons of measurements were analyzed by two-sided t
tests with a level of significance set at a minimum of p = 0.05.
Computational studies
Molecular systems were prepared from a crystal structure of
the NS3-4A protease WT bound to the N-terminal cleavage
product of MAVS (PDB 3RC5) (39). We modeled both full-
length substrates, MAVS and NS4A/4B, prior to the peptide
bond cleavage. The P91–4 residues of MAVS, missing in the ex-
perimental structure, were rebuilt based on the crystal struc-
ture of bovine chymotrypsin bound to eglin C (PDB 1ACB)
(40), as previously performed (41). Topologies and starting
coordinates for molecular dynamics simulations of protease
WT and mutants bound to MAVS and NS4A/4B substrates
were prepared using the tleap program of AmberTools15 (42),
minimized in gas phase while restraining the protein backbone.
The structures were then solvated and neutralized in a box of
SPC/E water molecules (43) using a minimum distance of
14.0 Å between the boundary and the protein atoms. All cal-
culations were performed with the Amber14/AmberTools15
suite of programs (41) using the ff03.r1 Amber force field (44,
45). After minimization and adjustment of the box size to
reach a target density of 1,000 kg/m3, the systems were gradu-
ally heated up to 300 K in the NVT ensemble (45). Finally,
production runs were performed for 250 ns in the NPT en-
semble at 300 K and 1 bar. Both heat-up and production runs
used a time step of 1 fs, and SHAKE bond-length constraints
were applied to all bonds involving hydrogen atoms. Temper-
ature and pressure were controlled with Langevin dynamics
(collision frequency of 4.0 ps21) and isotropic position scal-
ing, respectively.
Analysis of the trajectories was performed on frames
extracted from the last 100 ns of the NPT production simula-
tions. Analysis and visualization of residue-interaction net-
works was carried out using our in-house interaction network
plugin CONAN (manuscript in preparation) for Cytoscape
3 (46). Hydrogen bonds present in each time frame were
extracted from MD trajectories using cpptraj (46) with a maxi-
mum donor-acceptor distance of 3.5 Å and a minimum donor-
hydrogen–acceptor angle of 135°. Edge widths in the networks
shown represent the average number of H-bonds during simu-
lation time. Only edges above a minimum simulation presence
of 10% are shown. Cation-p stacking interactions between argi-
nine and histidine residues were analyzed by considering side-
chain distances and relative orientations. The side-chain plane
was defined for the Arg and His residues based on the heavy
atoms of the side-chain guanidinium group and imidazole
ring, respectively. In this scheme, an interaction was counted
as present if the distance between the center of mass of the
two planes did not exceed 5.0 Å, and if the angle between the
plane normal vectors was found in the ranges of 0–30° or
150–180°. Protein-substrate interaction energies were obtained
from the “Delta G gas” term as calculated by MMPBSA.py
(AmberTools17) (47–49). The error of uncorrelated sam-
ples se was estimated by an autocorrelation time analysis
(48), using a weighted single exponential fit (weight factor
1/(x 1 1)), where x is the integer distance between frames.
To reduce noise in the fit, only autocorrelation values larger
than 0.1 were used.
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All data that support the findings of this study are available
from the corresponding author upon request.
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